# Nucleus Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nucleus-genomics

- Industry: Biotechnology
- Headquarters: US
- Website: www.mynucleus.com
- Total disclosed funding: $32M
- Latest round: Series A (Jan 30, 2025)
- Investors on record: 15

## About

Nucleus Genomics Inc. is a US-based biotechnology firm specializing in advanced genomic testing that empowers individuals with insights into their health risks and genetic profiles through cutting-edge DNA sequencing.Nucleus Genomics Inc. provides comprehensive genomic testing services that analyze 100% of an individual's DNA for health insights. Founded in 2021, the company has successfully raised USD 14.00 mn in Series A funding on January 30, 2025, led by 776 and Founders Fund, with participation from various investors. The founder, Kian Sadeghi, also serves as the CEO.Nucleus offers advanced genomic testing services designed to provide comprehensive insights into individual health risks and genetic predispositions. Their core product includes a proprietary DNA sequencing analysis that assesses 100% of a person's DNA, significantly exceeding the depth of sequencing offered by competitors. This service facilitates the selection of embryos for families seeking IVF and delivers actionable health information that can guide lifestyle choices and preventive care. Nucleus serves a diverse clientele, including families planning for healthy children, individuals seeking personalized health insights, and healthcare providers looking for reliable genetic data to inform patient care. The company's services are available in several geographical markets, including North America and Europe, catering to consumers who wish to leverage genetic data for improved health outcomes.Nucleus generates revenue primarily through direct-to-consumer transactions, where individuals pay for DNA testing services that provide detailed health risk assessments. Customers purchase a testing kit, which they can complete from home with a simple cheek swab. Following sample submission, customers receive a comprehensive report highlighting their genetic predispositions to various health conditions, influencing their healthcare decisions. Pricing plans and costs associated with services are transparently outlined on the company’s platform, enabling informed customer choices. Nucleus positions itself uniquely in the genetic testing market, emphasizing the importance of informed health management through genetic insights.Nucleus Genomics Inc. plans to leverage its recent Series A funding of USD 14.00 mn raised in January 2025 to further develop its medical health technology. The company aims to introduce new products that enhance their genomic testing capabilities, although specific product release dates have yet to be disclosed. Additionally, Nucleus is targeting expansion into new markets, with a focus on increasing its presence in North America and Europe by the end of 2025.

## Funding rounds

- Series A, Jan 30, 2025, $14M — Founders Fund, Neo Ventures, 776, Rose Street Capital, Common Metal, Asylum Ventures, Giant Step Capital, One Eight Capital
- Seed, Jul 14, 2022, $14M — Founders Fund, Salt Funds Management, Quiet Capital, Shrug Capital, 776, Pareto Holdings, Pomp Investments, Night Ventures, Bluewatch Ventures
- Seed, Dec 15, 2021, $3.5M — Founders Fund, Salt Funds Management, Quiet Capital, Shrug Capital, Pareto Holdings, Pomp Investments, Night Ventures, Bluewatch Ventures

## Investors

- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Seed, Series A
- Salt Funds Management — Seed
- Quiet Capital (https://capitalatlas.ai/funds/quiet-capital) — Seed
- Shrug Capital (https://capitalatlas.ai/funds/shrug-capital) — Seed
- Pareto Holdings (https://capitalatlas.ai/funds/pareto-holdings) — Seed
- Pomp Investments (https://capitalatlas.ai/funds/pomp-investments) — Seed
- Night Ventures (https://capitalatlas.ai/funds/night-ventures) — Seed
- Bluewatch Ventures (https://capitalatlas.ai/funds/bluewatch-ventures) — Seed
- 776 (https://capitalatlas.ai/funds/776) — Seed, Series A
- Neo Ventures — Series A
- Rose Street Capital (https://capitalatlas.ai/funds/rose-street-capital) — Series A
- Common Metal (https://capitalatlas.ai/funds/common-metal) — Series A
- Asylum Ventures (https://capitalatlas.ai/funds/asylum-ventures) — Series A
- Giant Step Capital (https://capitalatlas.ai/funds/giant-step-capital) — Series A
- One Eight Capital (https://capitalatlas.ai/funds/one-eight-capital) — Series A